Kilambi News
Saturday, November 21, 2026

Erasca KRAS data raise pressure on Revolution's Rasonque

Life Sciences Saturday, November 21, 2026 - Updated Nov 21, 2026 07:13

Erasca's experimental drug ERAS-0015 produced responses in 44 percent of patients with KRAS mutated pancreatic cancer in a 122 patient Phase 1 study, with response rates of 63 percent and 80 percent in the G12D and G12V subgroups, and the company will move quickly into a Phase 3 trial.

Why it matters: The readout is the first credible competitive pressure on Revolution Medicines' Rasonque, whose own response rates in comparable testing were lower, although the comparison is cross trial and analysts are split on whether Erasca's early profile will survive a larger study.

Data as of BioPharma Dive report of November 20, 2026, read in full, on Erasca's Phase 1 results presented at a medical meeting on November 20, 2026; Endpoints News covered the same data the same day. Response rates are Erasca's as reported; the Rasonque comparison figures are from Revolution's earlier testing as reported by BioPharma Dive, and the two drugs have not been tested head to head.

Erasca said 44 percent of people with KRAS mutated pancreatic cancer responded to its experimental treatment ERAS-0015 in a small Phase 1 trial, supporting a decision to advance the medicine quickly into a Phase 3 study. Response rates were higher in the two largest mutation subgroups, 63 percent in G12D and 80 percent in G12V, which together cover around two thirds of people with KRAS mutated disease. Side effects were mostly mild and nobody stopped treatment because of them, the company said. The study covered 122 people whose pancreatic cancer had progressed after two or more treatment lines, at daily doses of 16 to 32 milligrams.

The data put early pressure on Revolution Medicines’ Rasonque, already on the market and off to one of the strongest oncology launches on record. In its own testing, Rasonque produced responses in 32 percent of the overall population and in 24 percent and 50 percent of G12D and G12V patients respectively, and it is associated with frequent skin rashes. Cross trial comparisons are unreliable and the drugs have not been tested head to head. RBC Capital Markets analyst Leonid Timashev called ERAS-0015 potentially a formidable competitor; TD Cowen’s Tyler Van Buren countered that the early results do not meaningfully differentiate from Rasonque given its multi year commercial head start.

Revolution also released new data this week from an early stage trial of Rasonque combined with chemotherapy in first line pancreatic cancer, where the combination produced responses in 61 percent of patients and left 8 percent with no evidence of active disease. Alterome Therapeutics, another RAS focused company, reported responses in 31 percent of KRAS mutated colorectal cancer patients for its drug ALTA3263 combined with Erbitux.

Sources

  1. Erasca data add to pressure facing Revolution's breakthrough cancer drug - BioPharma Dive - 2026-11-20
  2. KRAS at Triple Meeting: Erasca wants to one-up RevMed, while Alterome tries a different approach - Endpoints News - 2026-11-20